Physician profile
Daniel J Morris
NPI 1265595060
$3,668.88
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,161 · 2020: $476 · 2021: $13.69 · 2022: $18.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $445.23 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $370.62 | 2019-2020 | |
| Amgen INC. | $351.85 | 2019-2020 | |
| Genentech USA, INC. | $283.12 | 2019 | |
| Celgene Corporation | $233.62 | 2019-2020 | |
| Lilly USA, LLC | $175.27 | 2019-2020 | |
| Astellas Pharma US INC | $174.69 | 2019-2020 | |
| Genzyme Corporation | $173.55 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $162.56 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $156.94 | 2019 | |
| Janssen Biotech, INC. | $153.62 | 2019-2020 | |
| Pfizer INC. | $153.59 | 2019-2020 | |
| Seagen INC. | $111.07 | 2019-2020 | |
| Foundation Medicine, INC. | $87.90 | 2019 | |
| Clovis Oncology, INC. | $73.15 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurobindo Pharma USA, INC. | $54.82 | 2019 | |
| Eisai INC. | $51.22 | 2019 | |
| Heron Therapeutics, INC. | $47.46 | 2019 | |
| Rigel Pharmaceuticals, INC. | $47.21 | 2019-2020 | |
| Abbvie INC. | $45.09 | 2019-2021 | |
| Puma Biotechnology, INC. | $42.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.98 | 2019 | |
| Partner Therapeutics, INC. | $38.75 | 2019 | |
| Emd Serono, INC. | $32.90 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $30.85 | 2019 | |
| Incyte Corporation | $21.55 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.10 | 2019 | |
| Karyopharm Therapeutics INC. | $16.11 | 2020 | |
| Array Biopharma INC | $15.52 | 2020 | |
| Exelixis INC. | $14.67 | 2019 | |
| Agios Pharmaceuticals, INC. | $13.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.16 | 2019 | |
| Veracyte, INC. | $1.58 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.